Episode
Talking with Dr. Neil Anand
We speak with physician champion Dr. Neil Anand about his journey to empower physicians disenfranchised by overzealous regulatory agents. #opioids ...
A call to endorse formal complaint against the CDC
We speak with esteemed chronic pain patient advocate, Dr. Richard "Red" Lawhern, to seek endorsements for his formal complaint against ...
Asking for support for IL HB5373
We speak with patient advocate Kat H to garner support for HB5373, a legislative bill that has already passed unanimously ...
Braving through healthcare injustice with Dr. Barbara Marino
We speak with Dr. Barbara Marino, who endured much injustice at the hands of the DEA and DOJ, which remain ...
Daily Remedy health law courses now available
Daily Remedy courses are now available for public consumption. We offer courses on matters of health and law. Please review ...
Exposing DEI in Medicine
Dr. Jeffrey Singer and Professor Erec Smith discuss Diversity, Equity, and Inclusion initiatives in medical schools - and their potential ...
Daily Remedy Courses
Daily Remedy unveiled two courses for physicians and health administrators to participate in. The first course explains how to develop ...
Counterintuitive nature of health policy and healthcare
We discuss the voting power the health issue of abortion carries and how that affects both health policy and healthcare. ...
Reflecting on healthcare trends with Dr. Lynn Webster
Dr. Lynn Webster is a Senior Fellow at the Center for U.S. Policy, specializing in healthcare policy and patient care. He ...
Redefining learning in medicine at Daily Remedy
We detail major changes taking place to the website in the coming weeks. And we welcome your input! To let ...
Fighting for Justice for Dr. Bockoff and His Chronic Pain Patients
My name is Kristen Ogden and I advocate for chronic pain patients. My husband, Louis Ogden, is one of the ...
Empowering Physicians with Dr. Dana Corriel
Dana Corriel, MD, is a traditionally-trained physician who swapped clinical practice for digital entrepreneurship for innovation. After discovering she had ...
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read more